Intelligent Bio Solutions (INBS): Oct 13 Form 8-K, FDA 510(k) Fingerprint Drug Screening & Peer Brief vs. OCGN, INO, BCLI
INBS
Intelligent Bio Solutions Inc. (Nasdaq: INBS) commercializes non-invasive, fingerprint-sweat point-of-care drug screening systems across workplace safety, logistics, law enforcement, and rehabilitation markets in the UK, Europe, and Asia-Pacific while advancing U.S. FDA 510(k) clearance. On October 13, 2026, INBS filed a Current Report on Form 8-K (Items 5.03, 7.01, and 9.01) providing Regulation FD operational and corporate updates.
With a $5.24 million Nasdaq market capitalization, INBS combines active international commercial hardware-plus-consumable cartridge revenue with a binary U.S. FDA 510(k) market entry catalyst. While clinical biotech peers such as Ocugen (OCGN), Inovio (INO), and BrainStorm (BCLI) face multi-year Phase 3 timelines, medical device 510(k) clearance offers a faster regulatory path into the multi-billion-dollar U.S. workplace drug testing market.
Sector Peer Valuation & Catalyst Comparison
| Ticker | Company | Exchange | Market Cap | Primary Catalyst & Sector Focus |
|---|---|---|---|---|
| INBS (Subject) | Intelligent Bio Solutions Inc. | Nasdaq | $5.24M | Form 8-K (2026-10-13) · Non-Invasive Point-of-Care Diagnostics & MedTech |
| $OCGN | Ocugen, Inc. | Nasdaq | $260M | FDA clinical regulatory catalysts & specialty biologics |
| $INO | Inovio Pharmaceuticals, Inc. | Nasdaq | $98.0M | Device-enabled CELLECTRA diagnostics/delivery & BLA path |
| $BCLI | BrainStorm Cell Therapeutics | Nasdaq | $11.4M | Late-stage FDA regulatory catalysts & diagnostic biomarkers |
Verified SEC EDGAR Filing Metrics (INBS · CIK 0001725430)
| Form | Filing Date | Disclosure Scope | EDGAR Source |
|---|---|---|---|
| DEF 14A | 2026-11-02 | SEC Form DEF 14A | View EDGAR Filing → |
| 8-K | 2026-10-13 | SEC Form 8-K (Items: 5.03,7.01,9.01) | View EDGAR Filing → |
| S-3 | 2026-09-15 | SEC Form S-3 | View EDGAR Filing → |
| 8-K | 2026-09-11 | SEC Form 8-K (Items: 8.01) | View EDGAR Filing → |
| 8-K | 2026-09-09 | SEC Form 8-K (Items: 7.01,8.01,9.01) | View EDGAR Filing → |
What Active Traders & Microcap Desks Are Watching Next
MedTech and small-cap healthcare investors in our verified vault are focused on: (1) FDA 510(k) submission and clearance timeline for opiate and multi-drug fingerprint screening, (2) recurring test cartridge reorder rates across existing international accounts, and (3) cash runway through U.S. commercial launch.
Primary sources (SEC EDGAR)
INBS Form DEF 14A (2026-11-02): https://www.sec.gov/Archives/edgar/data/1725430/000149315226049613/formdef14a.htmINBS Form 8-K (2026-10-13): https://www.sec.gov/Archives/edgar/data/1725430/000149315226046863/form8-k.htmINBS Form S-3 (2026-09-15): https://www.sec.gov/Archives/edgar/data/1725430/000149315226042775/forms-3.htmINBS Form 8-K (2026-09-11): https://www.sec.gov/Archives/edgar/data/1725430/000149315226042411/form8-k.htmSee the dilution and promotion flags before you see the pitch.
Each week: the micro and small-caps now showing dilution or paid-promotion signals, with the SEC filing behind every flag. No recommendations, no price targets.